Timing the Stem Cell Opportunity
Executive Summary
Companies are drawing parallels between the monoclonal antibody industry and stem cells, and they are trying to strike a balance between gaining a stake in a field with tremendous potential without being too early. Stem cells have the potential to treat some of the largest degenerative diseases in the cardiovascular, neurological, orthopedic segments--markets worth in the double digit billions, according to a recent report on Tissue Engineering, issued by Medtech Insight. No company wants to be left behind.
You may also be interested in...
Multiple Paths of Convergence in Tissue Engineering
A collaboration within Carnegie Mellon is using ink-jet printing technology to create spatial patterns of growth factors, and in turn using them to influence the development of stem cells in vitro. The technology could provide a better means of harnessing the power of growth factor biology in regenerative medicine. The team is also using it to begin to develop rudimentary artificial bone-tendon-muscle constructs for eventual clinical use.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.